Maplight Therapeutics Inc. — Sponsor Intelligence | 2 EU Trials

Filter these 2 trials by condition, phase, country and more.

2 Registered trials

1 Recruiting

0 Completed trials

9 Countries active

1 Unique IMPs

N/A Results reported

Phase II

Top indications

2 total

An Open-Label Study of ML-007C-MA in Adults with Alzheimer’s Disease Psychosis Pending

2025-521757-16-00 Phase II 9 countries FESOTERODINE, 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOL…
A Study of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis Recruiting

2024-519820-26-00 Phase II 9 countries FESOTERODINE, 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOL…

Showing 1–2 of 2 trials